制药公司GSK宣布了一系列战略性举措，以加强其研发能力并改善财务表现。1该公司将投资4亿英镑在剑桥建设新的研发中心，同时关闭历史悠久的斯蒂文斯工厂，并将大部分科学家迁至新地点。1
为了支撑增长目标，GSK承诺到2029年削减19亿英镑的年度成本。1公司预计今年将能够将20种以上的潜在药物推进至后期试验阶段，相比之下去年这一数字仅为10种。1
GSK面临关键专利到期风险：其主力HIV药物dolutegravir约占集团销售额的五分之一，专利将在2028年至2030年期间到期。1公司目标在2031年实现400亿英镑以上的收入。1首席执行官Luke Miels从今年初开始担任职务，去年该公司还完成了近80亿美元收购美国癌症专家公司Nuvalent的交易。1
GlaxoSmithKline has announced a £400 million investment to construct a new research and development center in Cambridge, marking a strategic shift in the pharmaceutical company's operational footprint 1. The move will involve closing the historic Stevenage facility and relocating the majority of its scientific workforce 1.
The investment is coupled with an ambitious cost-reduction program, with GSK targeting £1.9 billion in annual cost cuts by 2029 1. Despite these efficiency measures, the company projects it can maintain or grow profit margins during the critical 2028-30 period when patents on its HIV drug dolutegravir—which accounts for approximately one-fifth of group sales—are set to expire 1. GSK aims to achieve revenues exceeding £40 billion by 2031 1. Chief Executive Luke Miels, who assumed the role at the start of this year, is overseeing these strategic initiatives 1.
The company also disclosed plans to advance more than 20 potential drugs into late-stage trials this year, compared with 10 in the previous year 1. This pipeline expansion follows GSK's acquisition of American cancer specialist Nuvalent for nearly $800 million last year 1.
评论
还没有评论，欢迎留下第一条。